Patients with mCRPC have a wide range of PSMA-expressing tumour burdens, causing a tumour sink effect on 68Ga-PSMA-617 PET/CT, which manifests as a decreasing uptake in healthy tissues as the TLF increases. Here, FOLH1 is linked to neoplasm.